- $2.18bn
- $2.78bn
- $14.75m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 147.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -104.94% | ||
| Return on Equity | n/a | ||
| Operating Margin | -2334.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.6 | 0.93 | 0.24 | 0.62 | 14.74 | 98.13 | 274.91 | 46.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Directors
- Patrick Soon-Shiong CHM (68)
- Richard Adcock PRE (52)
- David Sachs CFO (43)
- Sonja Nelson SVF (48)
- Sigrid Schreiner SVP
- Barry Simon OTH (56)
- Helen Luu OTH
- Michael Blaszyk IND (68)
- John Brennan IND (65)
- Wesley Clark IND (76)
- Cheryl Cohen IND (55)
- Linda Maxwell IND (47)
- Christobel Selecky IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 12th, 2014
- Public Since
- July 28th, 2015
- No. of Shareholders
- 80
- No. of Employees
- 680
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 881,929,108
- Address
- 3530 JOHN HOPKINS COURT, SAN DIEGO, 92121
- Web
- https://immunitybio.com/
- Phone
- +1 8586330300
- Auditors
- Ernst & Young LLP
Upcoming Events for IBRX
Immunitybio Inc Annual Shareholders Meeting
Q2 2025 Immunitybio Inc Earnings Release
Similar to IBRX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Immunitybio share price?
As of Today at 21:15 UTC, shares in Immunitybio are trading at $2.47. This share price information is delayed by 15 minutes.
How has the Immunitybio share price performed this year?
Shares in Immunitybio last closed at $2.47 and the price had moved by -52.86% over the past 365 days. In terms of relative price strength the Immunitybio share price has underperformed the S&P500 Index by -55.68% over the past year.
What are the analyst and broker recommendations for Immunitybio?
The overall consensus recommendation for Immunitybio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immunitybio dividend yield?
Immunitybio does not currently pay a dividend.
Does Immunitybio pay a dividend?
Immunitybio does not currently pay a dividend.
When does Immunitybio next pay dividends?
Immunitybio does not currently pay a dividend.
How do I buy Immunitybio shares?
To buy shares in Immunitybio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunitybio?
As of the previous close price of $2.47, shares in Immunitybio had a market capitalisation of $2.18bn.
Where are Immunitybio shares listed?
Here are the trading details for Immunitybio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IBRX
What kind of share is Immunitybio?
Based on an overall assessment of its quality, value and momentum Immunitybio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunitybio share price forecast for 2025?
The analyst consensus target price for shares in Immunitybio is $11.25. That is 355.47% above the last closing price of $2.47.
Analysts covering Immunitybio currently have a consensus Earnings Per Share (EPS) forecast of -$0.51 for the next financial year.
Find out moreWhat is the trend in the Immunitybio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunitybio. Over the past six months, its share price has underperformed the S&P500 Index by -22.9%.
As of the last closing price of $2.47, shares in Immunitybio were trading -36.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunitybio PE Ratio?
The Immunitybio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunitybio?
Immunitybio's management team is headed by:
- Patrick Soon-Shiong - CHM
- Richard Adcock - PRE
- David Sachs - CFO
- Sonja Nelson - SVF
- Sigrid Schreiner - SVP
- Barry Simon - OTH
- Helen Luu - OTH
- Michael Blaszyk - IND
- John Brennan - IND
- Wesley Clark - IND
- Cheryl Cohen - IND
- Linda Maxwell - IND
- Christobel Selecky - IND